The stock price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has surged by 2.19 when compared to previous closing price of 110.70, but the company has seen a 3.50% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-05-09 that Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.
Is It Worth Investing in Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Right Now?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has a price-to-earnings ratio that is above its average at 24.61x. The stock has a 36-month beta value of 0.63. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 4 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for JAZZ is 60.93M, and at present, short sellers hold a 6.08% of that float. On May 10, 2024, the average trading volume of JAZZ was 646.66K shares.
JAZZ’s Market Performance
JAZZ stock saw a decrease of 3.50% in the past week, with a monthly decline of -0.84% and a quarterly a decrease of -7.79%. The volatility ratio for the week is 2.47%, and the volatility levels for the last 30 days are 2.61% for Jazz Pharmaceuticals plc (JAZZ). The simple moving average for the last 20 days is 2.97% for JAZZ stock, with a simple moving average of -9.34% for the last 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Robert W. Baird repeating the rating for JAZZ by listing it as a “Outperform.” The predicted price for JAZZ in the upcoming period, according to Robert W. Baird is $160 based on the research report published on January 03, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $135, previously predicting the price at $170. The rating they have provided for JAZZ stocks is “Neutral” according to the report published on November 27th, 2023.
JAZZ Trading at -1.94% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.89% of loss for the given period.
Volatility was left at 2.61%, however, over the last 30 days, the volatility rate increased by 2.47%, as shares sank -0.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.78% lower at present.
During the last 5 trading sessions, JAZZ rose by +3.50%, which changed the moving average for the period of 200-days by -14.19% in comparison to the 20-day moving average, which settled at $109.84. In addition, Jazz Pharmaceuticals plc saw -8.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from Patil Neena M, who sale 5,000 shares at the price of $109.65 back on May 03 ’24. After this action, Patil Neena M now owns 36,629 shares of Jazz Pharmaceuticals plc, valued at $548,250 using the latest closing price.
Carr Patricia, the SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, sale 1,768 shares at $116.98 during a trade that took place back on Mar 07 ’24, which means that Carr Patricia is holding 6,596 shares at $206,821 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.85 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.11. The total capital return value is set at 0.07. Equity return is now at value 9.41, with 2.96 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.61 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.53. The interest coverage ratio of the stock is 2.13.
Currently, EBITDA for the company is 1.3 billion with net debt to EBITDA at 3.56. When we switch over and look at the enterprise to sales, we see a ratio of 3.04. The receivables turnover for the company is 5.43for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.15.
Conclusion
To sum up, Jazz Pharmaceuticals plc (JAZZ) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
